



January 21, 2022

Dr. Mujo Kim  
Representative Director and President  
**Pharma Foods International Co., Ltd.**  
1-49 Goryo-Ohara, Nishikyo-ku, Kyoto, Japan

- ❖ Towards the Expansion of Cognitive Health Market in North America
- ❖ Health Canada Recognizes Functional Properties of PharmaGABA®

We are pleased to announce that Health Canada has approved PharmaGABA® by Pharma Foods International Co., Ltd. as a functional food ingredient that contributes to the improvement of cognitive function (Cognitive Support).



PharmaGABA® has topmost global market share for GABA

	Health Canada	Santé Canada
<b>Product Licence Licence de mise en marché</b>		
Product Number/Numéro de produit: 80115488		
Brand Name/Marque nominative: PharmaGABA(r)		
Issued to/Émise à:		
Name of licensee/Nom du titulaire:		
Pharma Foods International Co., Ltd.		
1-49 Goryo-Ohara, Nishikyo-ku		
Kyoto, , 615-8245		
Japan		

Part of the NHPs license

Health Canada's regulatory authority, NNHPD\*1, authorizes foods and functional ingredients that are used to maintain good health as Natural Health Products (NHPs) under the Natural Health Products Regulations. To sell NHPs in Canada, a license must be obtained from the NNHPD. In order to obtain this license, evidence of functionality and safety must be submitted to the NNHPD for their rigorous review.



PharmaGABA® has been shown to improve overall cognitive function and this approval from the NNHPD will allow Canadian manufacturers to market their products containing PharmaGABA® with cognitive function claims. PharmaGABA® has been adopted by several major Canadian manufacturers, such as Natural Factors group, and has already gained high recognition and trust. With the addition of new health claims, the market for PharmaGABA® is expected to expand further.

Adopted by major manufacturers like Natural Factors

Dr. Aditya Kulkarni, Manager of Overseas Business Development, said "PharmaGABA®'s NHPs certification is a testament to our R&D capabilities and high product quality. We are confident that it will be a

significant step towards obtaining the US-FDA's GRAS\*<sup>2</sup> certification in the United States. In U.S.A, the cognitive health market has shown a double-digit growth rate\*<sup>3</sup> for several years, and it is an area of high interest worldwide. This approval of the cognitive support health claims for PharmaGABA® will lead to increased sales of PharmaGABA® in the North American market.”

References:

\*1 <https://www.canada.ca/en/health-canada/corporate/about-health-canada/branches-agencies/health-products-food-branch/natural-non-prescription-health-products-directorate.html>

\*2 The certification as "Generally Recognized as Safe (GRAS)" by the U.S. Food and Drug Administration (FDA) will enable the addition of PharmaGABA® to various general foods and beverages and further lead to a broader market penetration.

\*3 Source: Credence Research “US Brain Health Supplements Market”